On this page
fluocinolone acetonide
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Fluocinolone Acetonide | .1 mg/mL | 1191310 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 088167-001 | FLUOCINOLONE ACETONIDE | SOLUTION | FLUOCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 6 | Labeling | Approved | April 11, 2005 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | June 24, 1996 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | March 9, 1988 | — |
| Original application | 1 | Approved | December 16, 1982 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260128). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution USP, 0.01% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Fluocinolone Acetonide Topical Solution USP, 0.01% is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Description
openFDA Drug LabelingDESCRIPTION Fluocinolone Acetonide Topical Solution USP, 0.01% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-,(6α,11β,16α)-. It has the following chemical structure: Fluocinolone Acetonide 0.01% Solution (each mL contains 0.1 mg Fluocinolone Acetonide) in a water-washable base containing citric acid and propylene glycol. Chemical Structure
Overdosage
openFDA Drug LabelingOVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Fluocinolone Acetonide Topical Solution USP, 0.01% 60 cc Bottle with applicator tip – NDC 43386-069-60 STORAGE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc at 1-866-403-7592 or FDA at 1-800-FDA-1088 or www.fda/gov/medwatch. Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Novel Laboratories, Inc. Somerset, NJ 08873 PI0690600202 Rev. 06/2017
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FLUOCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class III | January 21, 2026 | SUN PHARMACEUTICAL INDUSTRIES INC | Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D. | Ongoing |
| Class II | January 30, 2019 | LUPIN SOMERSET | Failed Impurities/Degradation Specifications: Expansion of October 2018 recall due to elevated out of specification results for total impurities that have been chemically identified as oxidative degradation products of the fluocinolone active pharmaceutical ingredient. | Terminated |
| Class II | October 31, 2018 | LUPIN SOMERSET | Failed Impurities/Degradation Specifications:Out of specification result noticed for total impurities observed during stability analysis | Terminated |
| Class III | April 19, 2017 | Novel Laboratories, Inc. | Chemical Contamination | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0168-0059-60 | 0168-0059 | Fougera Pharmaceuticals, LLC | 60 mL in 1 BOTTLE (0168-0059-60) | December 16, 1982 |
| 43386-069-60 | 43386-069 | Lupin Pharmaceuticals,Inc. | 1 BOTTLE in 1 CARTON (43386-069-60) / 60 mL in 1 BOTTLE | September 2, 2015 |
| 51672-1365-2 | 51672-1365 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE in 1 CARTON (51672-1365-2) / 20 mL in 1 BOTTLE | March 27, 2015 |
| 51672-1365-4 | 51672-1365 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE in 1 CARTON (51672-1365-4) / 60 mL in 1 BOTTLE | March 27, 2015 |
| 0168-0059 | 0168-0059 | Fougera Pharmaceuticals, LLC | — | December 16, 1982 |
| 43386-069 | 43386-069 | Lupin Pharmaceuticals,Inc. | — | September 2, 2015 |
| 51672-1365 | 51672-1365 | Sun Pharmaceutical Industries, Inc. | — | March 27, 2015 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.